Skip to content

NTHI NTHI Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Pfizer logo
PfizerPFE
$1.76B+18.8%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$25.13M-15.9%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$56.4M+14.3%
Nuvation Bio logo
Nuvation BioNUVB
$125.39M+161%

Other financials

Income statement

See full
Revenue$40.0K-7.0%
Operating income-$7.1M+77.9%
Net income-$8.8M+72.7%
EPS (diluted)-$0.38+78.7%

Balance sheet

See full
Total debt$666.1K
Total equity-$13.2M-37.5%
Total assets$3.3M-60.6%

Cash flow

See full
Operating cash flow-$7.0M-23.7%
CapEx$125.0K
Free cash flow-$5.2M

Valuation

See full
Market cap$114.62M+51.0%
Enterprise value$115.15M+51.1%
P/S1,432.9×

Profitability

See full
Operating margin-46,870.7%
Net margin-51,613.3%
FCF margin-26,083.2%

Returns & leverage

See full
Return on equity338.1%
Debt / equity-0.1×
Current ratio0.1×-0.3×

Where this comes from

Reported directly by NTHI in its filing.

Tagged under the XBRL concept us-gaap:Cash.

The official record: NTHI’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about NTHI's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NTHI's cash & equivalents?
NTHI (NTHI) reported cash & equivalents of $138.6K in Q1 2026.
How has NTHI's cash & equivalents changed year-over-year?
NTHI's cash & equivalents decreased by 97.5% year-over-year, from $5.44M to $138.6K.
What is the long-term trend for NTHI's cash & equivalents?
Over 2 years (2023 to 2025), NTHI's cash & equivalents has grown at a 35.8% compound annual growth rate (CAGR), from $31.86K to $58.73K.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.